Matricelf Partners with Sheba Medical Center for Spinal Cord Injury Clinical Trials

Key Facts

1Matricelf (TASE: MTLF) announced a strategic collaboration with Sheba Medical Center to support its first-in-human clinical trial for spinal cord injury.

2Sheba Medical Center is ranked 7th globally by Newsweek.

3The program focuses on developing autologous engineered neural tissue therapies in the field of regenerative medicine.

Matricelf (TASE: MTLF) has announced a strategic collaboration with Sheba Medical Center to support its inaugural first-in-human clinical trial. The partnership focuses on advancing regenerative medicine therapies specifically designed for spinal cord injuries. The clinical program involves the development of autologous engineered neural tissue, a cutting-edge approach in the biotechnology sector. By collaborating with Sheba Medical Center, which is ranked 7th globally by Newsweek, Matricelf gains access to world-class clinical infrastructure and expertise. This milestone is expected to significantly reduce execution risks as the company transitions into the critical clinical phase. Investors view this move as a major step forward in validating Matricelf’s technology and its potential for future commercialization.